Di seguito l'elenco completo dei nostri comunicati stampa (pagina 7 di 28):
AbbVie’s ELAHERE® approved in the EU for FRα-positive platinum-resistant ovarian cancer, showing survival benefits.
Ratio Therapeutics collaborates with Novartis on SSTR2-targeting radiopharmaceutical for cancer, worth $745M.
Dogwood reveals IMC-2 reduces Long-COVID fatigue at low doses; high doses cause GI side effects, limiting efficacy.
Preclinical results for Silo Pharma's SPC-15 reveal enhanced efficacy for depression via dual-receptor targeting therapy.
HCW Biologics partners with WY Biotech in a global agreement to develop and commercialize a novel immunotherapy.
Min Park named Chief Commercial Officer at Matica Bio, leveraging 25+ years of experience in global life sciences.
IDEAYA Biosciences names Stu Dorman as Chief Commercial Officer, bringing 20+ years of oncology expertise to lead its commercial efforts.
Sapio Sciences partners with Waters Corporation to boost lab efficiency and data accuracy through LC-MS and LIMS integration.
Sakura and MEDIPATH partner to improve cancer diagnostics in France using automated Tissue-Tek AutoTEC® a120 systems.
Scorpius Ventures supports biotech firms with cGMP services and equity stakes, boosting U.S. biologics production.
ImmunityBio's ANKTIVA-BCG therapy achieves a 71% complete response rate in bladder cancer, with durable responses reaching 54 months.
Abzena launches GMP cell-based potency assays in UK and US, boosting bioassay services for biopharmaceutical development.
Mirai Bio appoints Jens Vogel, Ph.D., as President and COO to accelerate genetic medicine development and in vivo delivery systems.
Steritas and argenx collaborate to use STOX® Suite in trials, addressing steroid toxicity in autoimmune disease treatments.
Merck's subcutaneous pembrolizumab shows noninferiority to intravenous KEYTRUDA in efficacy and safety for metastatic NSCLC.
Simon Fry joins Conduit Pharmaceuticals' Board, bringing over 30 years of experience in investment banking.
Circio partners with Certest Biotec to formulate circVec-LNPs for tissue-specific gene therapy targeting genetic diseases.
Asimov partners with RevOpsis to advance RO-104, a tri-specific biologic targeting retinal vascular diseases.
The Recursion-Exscientia merger combines AI expertise to advance drug discovery, expanding clinical and preclinical pipelines.
Capricor's deramiocel receives Orphan drug and ATMP designations, boosting the development of Duchenne muscular dystrophy therapy.
Voyager selects VY1706 for Alzheimer’s, with promising tau reduction results in preclinical NHP studies.
Pfizer names Dr. Chris Boshoff as Chief Scientific Officer and R&D President, effective January 2025, succeeding Dolsten.
Ziihera gains FDA acceptance for HER2-positive BTC; Phase 2b data show a 52% response rate and confirmatory trials are in process.
Samsung Biologics announces USD 668M in contracts, expands ADC services, and plans a new Bio Campus II.
BIMZELX (bimekizumab) receives FDA approval for moderate-to-severe hidradenitis suppurativa treatment in adults.
WHO announces ethical principles for managing genomic data, emphasising informed consent, equity, and transparency.
Alloy Therapeutics and Takeda partner to advance iCAR-T and iCAR-NK cell therapies for cancer treatment using iPSC technology.
Pfizer's HYMPAVZI™ wins EU nod as the first anti-TFPI therapy for severe hemophilia A & B, enabling once-weekly dosing with an auto-injector.
Syntegon achieves SBTi validation for climate goals, aiming for 48.3% Scope 1 & 2 emissions reductions by 2030 and greener operations.
Amneal progresses with FDA resubmission for migraine autoinjector and approval of exenatide for type 2 diabetes.
Protagonist advances PN-881, an oral IL-17 antagonist, into preclinical studies for immune-driven skin conditions.
Conduit Pharmaceuticals earns Japan patent for AZD1656, advancing its portfolio of autoimmune disorder treatments
CNSide CSF Assay detects biomarker changes in LM patients, the data to be presented at SNO 2024 in Houston.
Novartis acquires Kate Therapeutics for $1.1B to enhance gene therapies targeting neuromuscular diseases.
Genpact renewed its partnership with Ferring to streamline finance, accounting, and procurement, including AI.
Vetter appoints three senior leaders to its management team to drive sustainable growth and meet global customer needs, starting January 1, 2025.
Transposon Therapeutics acquires nucleoside analogs from PrimeFour, boosting its oncology pipeline with potential for targeted cancer treatments.
Dr. Reddy's names Vaibhav Rane as Head of Project Management at R&D Centre to optimize product strategies.
Merck welcomes Emerson’s CEO, Surendralal Karsanbhai, to its board, further strengthening its leadership team in 2025.
CNSide’s FORESEE trial shows superior accuracy and treatment impact for breast and lung cancer patients with LM.
Globus Medical’s ExcelsiusHub™ revolutionises spine surgery with real-time navigation, imaging flexibility, and safety features.
Merck’s WELIREG gains approval in China for VHL disease, demonstrating significant tumour response in critical trials.
Japan expands approval for GSK’s Arexvy, allowing use in adults 50-59 at high risk of severe RSV disease.
Gattefossé opens a state-of-the-art Mumbai Technical Center, advancing pharmaceutical and personal care R&D in India.
Kim Kyung-jin joins Samyang as biopharma president, driving CDMO expansion and advancing mRNA delivery technologies.
Firebrick partners with Guardian to make Nasodine available in 121 pharmacies, including Changi Airport outlets.
Truqap (capivasertib) with abiraterone and ADT boosts survival in PTEN-deficient prostate cancer, showing promising results in a Phase III trial.
Ascentage Pharma appoints Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors to enhance governance and support growth.
Hanmi's BH3120 immunotherapy, targeting PD-L1 and 4-1BB, shows promise in Phase 1 trials for solid tumors.
Pharma Now proudly announces its media partnership with Evolution Summit 2024, spotlighting pharma industry innovation.
Qosina names Lee Pochter as CEO, with Scott Herskovitz continuing as Chair and Medical Division President.
Lee Patterson named CEO of Metrion Biosciences, focusing on growth and global presence as Dr. Andrew S. steps down.
Delegates unite at WHO’s first oral health summit to address global challenges and ensure balanced care access.
Eton Pharmaceuticals secures U.S. rights to Amglidia for neonatal diabetes, aiming for FDA approval by 2026.
iiCON leads a £3.2M trial for PnuBioVax, tackling resistant pneumococcal strains like SPN3 to combat global health and antimicrobial resistance.
Citius Pharma advances Mino-Lok program post-FDA Type C meeting, aiming for NDA submission after pivotal Phase 3 success.
Merck reports vital Phase 3 ZENITH trial results for WINREVAIR in pulmonary arterial hypertension (PAH).
Arlington Capital Partners acquires TEAM Technologies, enhancing healthcare manufacturing and strategic supply solutions.
Dr. Deyaa Adib joins AffyImmune as CMO, bringing decades of oncology expertise to advance (CAR) T therapies.
IGC Pharma reports Phase 2 interim data showing IGC-AD1 reduces agitation and enhances cognition in Alzheimer's trials.
Biohaven’s taldefgrobep shows motor function and fat mass benefits in SMA, with potential for obesity treatment progress.
Freudenberg strengthens its commitment to India with innovative product launches at CPhI & PMEC 2024, driving industry growth.
Island Pharmaceuticals’ ISLA-101 shows safety and antiviral activity in Phase 2a dengue trial, with Phase 2b set to start in January 2025.
Dr. Reddy's, in collaboration with Senores Pharmaceuticals, introduces Ivermectin 3 mg tablets in the U.S. market.
Shuttle Pharma launches Phase 2 trial of ropidoxuridine, targeting improved radiation therapy outcomes for glioblastoma.
Afatinib, combined with DFP-14323, receives a seal of approval in Japan's 2024 guidelines for NSCLC therapy.
Tillotts Pharma and Pioneer Pharma team up to distribute Asacol® 800mg in China, addressing the rising prevalence of ulcerative colitis.
Roche announces SKYSCRAPER-01 trial results, with tiragolumab plus Tecentriq missing the overall survival endpoint in PD-L1-high NSCLC.
Acadia signs a global licensing deal with Saniona to develop SAN711 for essential tremor, aiming for Phase 2 trials in 2026.
Nexus Pharmaceuticals secures FDA approval for Methylene Blue Injection to treat methemoglobinemia, enhancing access to life-saving medication.
KalVista Pharmaceuticals appoints Laurence Reid, Ph.D., to its Board, bringing expertise in biotech growth, innovation, and strategic leadership.
Exelixis announces FDA review of CABOMETYX for advanced pNET and epNET, based on phase 3 CABINET trial data, at ODAC in March 2025.
Roche acquires Poseida Therapeutics to boost development of next-gen off-the-shelf CAR-T therapies, targeting oncology, immunology, and neurology.
Outlook Therapeutics reveals NORSE EIGHT trial results, showing vision improvement and safety, with a BLA resubmission planned for Q1 2025.
Glenmark introduces Travoprost Ophthalmic Solution, bioequivalent to Travatan Z®, enhancing its U.S. product portfolio.
Prelude Therapeutics will participate in the JMP Hematology and Oncology Summit, featuring a webcast fireside chat.
Syndax CEO Michael Metzger to discuss novel oncology mechanisms during the Citi 2024 Global Healthcare Conference panel.
BioStem signs a Letter of Intent to acquire revyve™ Wound Gel and technologies from ProgenaCare and Kane Biotech.
Carisma Therapeutics' CEO Steven Kelly to join a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on December 5th.
Amylyx Pharmaceuticals announces participation in the 7th Annual Evercore ISI HealthCONx Conference on December 4, 2024.
ADVANZ PHARMA reacts to the European Commission revoking OCALIVA® approval for PBC treatment in Europe.
Perspective Therapeutics to present at Piper and Evercore HealthCONx conferences, highlighting cancer treatment innovations and growth strategies.
Novartis gains EC approval for Kisqali® in HR+/HER2-early breast cancer, offering a new option to reduce recurrence risk in high-risk patients.
Nemolizumab shows significant improvements in itch, skin lesions, and sleep in prurigo nodularis, earning FDA approval as Nemluvio®.
Dev4All collaborates with Pharmaseed to integrate expertise to provide comprehensive preclinical drug development solutions.
Telix & Grand Pharma dose first patient in the Phase III ZIRCON-CP trial of TLX250-CDx PET imaging for kidney cancer at Beijing Cancer Hospital.
Dr. Reddy’s launches Toripalimab in India, advancing RM-NPC treatment with immuno-oncology innovation.
Innovent adds SINTBILO® and olverembatinib to China's NRDL, expanding cholesterol and CML care options.
The WHO confirms mpox as a public health emergency, emphasising coordinated international efforts and resources.
Lupin receives FDA approval for Sitagliptin and Metformin tablets, a generic Janumet®, enhancing diabetes care options.
Huons Biopharma partners with VERNI Aesthetics to commercialize MRC101, a fat decomposition injection, boosting its aesthetics portfolio and R&D efforts.
Bayer opens Co.Lab Berlin, a life science incubator, with MyoPax as its first resident, boosting biotech innovation and muscle regeneration research.
Silo Pharma collaborates with Kymanox to develop a ketamine implant and insertion device aimed at treating chronic pain and fibromyalgia.
WHO highlights critical gaps in preventing healthcare-associated infections, urging stronger IPC measures to protect patients and healthcare workers.
Evotec announces COO Dr Craig Johnstone's step down by December 2024; operations will be restructured internally.
ABIONYX adopts vital resolutions, including new director appointments and bylaw changes, at its 2024 General Meeting.
Nanolek and GC Biopharma seek approval for trials of a new chickenpox vaccine, aiming for registration by 2027.
Afreximbank and Med Aditus partner to build a $40M pharma plant in Kisumu, boosting medicine production in Kenya.
Nirmala Sitharaman calls for India to establish pharma standards, scale global innovations, and embrace an Indian identity.
NEXT BIOMEDICAL secures U.S. FDA approval for Nexpowder's use in treating lower GI bleeding, expanding its scope.
Brainomix earns LSX and OBN honors for its AI imaging platform, driving advances in stroke care and lung fibrosis treatment worldwide.
CBC Group and Mubadala acquire UCB's neurology and allergy assets in China, launching NeuroGen Pharma for growth.
Experience 12x faster MRI scans with GE HealthCare’s Sonic DL for 3D, enhancing imaging for neurology, orthopedics, and body exams.
Everest Medicine’s VELSIPITY® NDA accepted in Hong Kong for treating moderately to severely active ulcerative colitis.
FDA approves Biocon Biologics' YESINTEK™, a Stelara® biosimilar for Crohn's, Ulcerative Colitis, psoriasis, and arthritis.
Bayer highlights AI advancements, low-dose contrast agents, and smart imaging systems at RSNA 2024, enhancing radiology workflows and patient care.
GE HealthCare introduces AI-powered technologies at RSNA 2024, aimed at improving radiology workflows, boosting efficiency, and enhancing patient care.
Merus will present updated data on petosemtamab for r/m HNSCC at ESMO Asia Congress 2024, Singapore.
Novocure’s Phase 3 PANOVA-3 trial shows TTFields therapy improves survival in pancreatic cancer, with 2-month advantage over standard chemo.
Medicus Pharma teams up with Swanielle Inc. to expand its Phase 2 BCC clinical trial into Asia-Pacific, accelerating global skin cancer treatment.
Mapi Pharma presents innovative Depot technologies at Evercore HealthCONx 2024, offering partnership opportunities for long-acting injectable treatments.
Orexo AB and GAIA AG end their Deprexis® partnership for the U.S., impacting Q4 2024 income but maintaining cash position and future profitability.
Eckert & Ziegler launches Ac-225 production, addressing shortages and paving the way for clinical radiopharmaceutical use.
IntegriChain presents at Trade & Channel Strategies, exploring pharma trends and AI-powered distribution insights.
PTC and Novartis partner on Huntington’s therapy, with $1B upfront, milestone payments, and U.S. profit-sharing.
Rigel’s R289 secures FDA Fast Track for transfusion-dependent lower-risk MDS, aiming to address unmet needs with its dual IRAK1/IRAK4 inhibitor.
TORL BioTherapeutics names Dr. Aran Maree as CMO and launches a Phase 2 trial for TORL-1-23 in CLDN6+ platinum-resistant ovarian cancer.
Medexus revises milestone payments for treosulfan, anticipates FDA approval by Jan 2025, and strengthens financial flexibility for U.S. launch.
AC Health collaborates with USAID to improve HIV care in the Philippines, expanding telehealth, testing, and access to essential medications nationwide.
Spyre initiates Phase 1 studies of anti-TL1A antibodies, with safety and pharmacokinetics data expected in 2025.
Eckhard Niemeler joins Nouscom as Chief Business Officer, bringing 20+ years of expertise in life sciences leadership.
Novo Nordisk presents groundbreaking data on sickle cell disease and hemophilia treatments at ASH 2024, focusing on unmet needs in rare blood disorders.
Jazz Pharmaceuticals showcases oncology and hematology data at SABCS and ASH 2024, focusing on HER2-positive cancers and blood disorders.
Keros licenses elritercept to Takeda for global development, focusing on anaemia and rare blood disorders.
Plus Therapeutics and IsoTherapeutics extend the partnership, ensuring scalable production of cGMP Re-186 for key treatments.
Recursion launches a trial for REC-1245, an AI-discovered therapy targeting biomarker-enriched tumours and lymphoma.
Lawrence Kenyon becomes Interim CEO of Outlook Therapeutics after Russell Trenary steps down from the role.
Martin Pharmaceuticals partners with Mitsubishi Tanabe for exclusive access to docarpamine data for GI conditions outside Japan.
Romaco Holding GmbH appoints Ann-Xiaoyan Li as Group CFO & Managing Director, overseeing finance, HR, IT, and operations to drive growth and efficiency.
Coeptis Therapeutics to acquire NexGenAI's AI marketing platform, boosting efficiency in biotech and pharma.
Ipsen and Biomunex collaborate on BMX-502, a bispecific antibody using MAIT cells to target cancer, offering safer, innovative immunotherapy solutions.
AstraZeneca appoints Iskra Reic as EVP for International, overseeing strategy and growth across key markets, including Asia, China, and Latin America.
Jazz will discuss Ziihera® approval, clinical trial data, and commercialisation plans in the upcoming webcast.
Corvus highlights soquelitinib’s mechanism to boost tumour immunity, with Phase 3 and Phase 1 trials underway for various uses.
X4 Pharmaceuticals will present Mavorixafor trial-in-progress data poster and preclinical data at the 2024 ASH Meeting, December 7-10.
Franklin Biolabs appoints Dr. Vatsala Naageshwaran as CEO, bringing over 20 years of experience in advancing gene therapy and biopharmaceutical operations.
Circio unveils circVec 3.0, a circular mRNA lasting 75x longer than linear mRNA, transforming nucleic acid medicine durability and safety.
Nxera Pharma announces Phase 3 trial of daridorexant for insomnia treatment in South Korea, with results expected by 2026.
Vincerx Pharma cuts costs to advance VIP943 Phase 1 study, focusing on innovative cancer treatment with its ADC therapy.
Atea Pharmaceuticals announces successful Phase 2 trial results for HCV treatment, paving the way for Phase 3 trials in early 2025.
Amylyx Pharmaceuticals initiates a Phase 3 trial for avexitide to treat post-bariatric hypoglycemia, building on promising Phase 2 study results.
Bayer and Liveo Research unveil innovative blister packaging with a reduced environmental footprint, setting new industry standards.
Plus Therapeutics will present Phase 1 ReSPECT-LM data at the 2024 San Antonio Breast Cancer Symposium, focusing on Rhenium Obisbemeda for LM treatment.
Merck starts Phase 3 clinical trial for LAGEVRIO, evaluating its effectiveness in high-risk COVID-19 patients to prevent severe disease.
Monte Rosa shares interim data from the MRT-2359 trial in MYC-driven cancers, highlighting safety, dosing, and pharmacodynamics.
Charles River announces its Incubator Program to support early-stage biotech companies in advancing therapies and innovation.
Theriva gains FDA input on Phase 3 study design for VCN-01 in combination with chemo for pancreatic cancer.
PDF Radiopharma announces Techne® Pyrophosphate Injection’s listing on Japan’s NHI, with a launch scheduled for February 2025.
Novartis announces positive results from Phase III3B APPULSE-PNH study of Fabhalta® in PNH patients switched from anti-C5.
FDA grants Imfinzi approval for LS-SCLC, offering improved survival rates and marking a major advance in treating this aggressive cancer.
MaaT Pharma treats its first U.S. aGvHD patient with MaaT013 under compassionate use, marking progress in life-saving microbiome therapies.
ProBio names Allen Guo as CEO, Whitney Winters as SVP, and Michael Vreeland as U.S. Site Head to drive innovation in advanced therapies.
Teva is selling its stake in the Teva-Takeda venture in Japan to JKI as part of its Pivot to Growth strategy, with completion expected by April 2025.
NorthStar and PDRadiopharma collaborate to advance innovative radiopharmaceuticals for clinical trials and cancer care.
FDA accepts Priority Review for Imfinzi in MIBC, with Phase III data showing reduced progression and improved survival.
Lupin secures FDA approval for its pediatric HIV treatment, a generic version of Triumeq PD®, made in Nagpur.
Torii submits NDA for TO-208 in Japan, marking progress toward the first approved molluscum contagiosum treatment.
Novo's Catalent acquisition gets EU approval; final steps and regulatory clearances are expected by year-end 2024.
WHO selects experts worldwide to update guidelines on advanced HIV care, focusing on CD4 testing and treatment strategies.
Enanta Pharmaceuticals announces December 9 webcast to share topline Phase 2 RSV study results in pediatric patients.
Jazz Pharmaceuticals presented new data at AES 2024, showing Epidiolex® improves seizure control and behavior in TSC and epilepsy patients.
Dr. Reddy's appoints Chiranjoy Chowdhuri as Head of Data and AI CoE to drive digital transformation and AI initiatives, enhancing business impact and growth.
Five-year POLARIX data highlights Polivy + R-CHP efficacy in DLBCL, reducing death risk and enhancing remission durability.
Calquence with venetoclax achieves better survival and safety outcomes than chemoimmunotherapy in CLL patients.
Leukogene appoints Dr. Gupta as CEO, leveraging his oncology expertise to drive its MT2™ platform for "cold" tumors.
Merck’s zilovertamab vedotin, in combination with R-CHP, hits 100% complete response rate in a Phase 2 trial for untreated DLBCL treatment.
AbbVie highlights emotional and cultural challenges among diverse CLL patients, emphasising gaps in support and communication.
Recce secures approval in Indonesia for a Phase 3 trial of RECCE® 327 Gel, advancing treatment for diabetic foot infections.
Tonix's TNX-102 SL, a sublingual cyclobenzaprine, shows promise in improving pain, sleep, and symptoms for fibromyalgia.
Hikma debuts FDA-approved Furosemide Injection in 50mL and 100mL forms, enhancing its U.S. injectable offerings.
Seres' FDA-designated SER-155 reduces bloodstream infections in allo-HSCT patients, showing transformative potential.
GSK's Nucala shows promise as an add-on therapy for COPD with eosinophilic phenotype, based on MATINEE study.
AbbVie reports positive Phase 3 results for tavapadon, a once-daily treatment for early-stage Parkinson's disease.
Enanta reports Phase 2 success for zelicapavir, showing strong antiviral effects and safety in RSV pediatric study.
Acurx advances ibezapolstat into Phase 3 trials for C. difficile, focusing on efficacy, safety, and recurrence prevention.
Syndax shares positive trial results for Revuforj in AML, including its use in combination therapies for new patients.
Recursion's Phase 1 data highlights REC-617's potential as a best-in-class CDK7 inhibitor for advanced solid tumors.
CARVYKTI® achieves 89% MRD negativity in relapsed multiple myeloma, showcasing transformative potential in the CARTITUDE-4 study.
Carisma shifts focus to its macrophage engineering platform, halting CT-0525 development and reducing the workforce.
Acadia names Thomas Garner as CCO to drive growth and promotes Holly Valdiviez to lead the NUPLAZID franchise.
Cellipont adopts Xiogenix's Ares™ X20, enhancing automation, scalability, and precision in cell therapy production.
Emmes names Bryan Patterson as Senior Vice President to drive growth and innovation in U.S. government clinical research efforts.
Cipher evaluates MOB-015 trial findings while prioritizing Natroba™ integration and future growth initiatives in key markets.
FDA clears Astria Therapeutics’ STAR-0310 IND for clinical trials targeting atopic dermatitis and other conditions.
Sound Pharmaceuticals' SPI-1005 Phase 3 trial achieves hearing and speech improvements for Meniere's disease patients.
CPHI & PMEC India 2024 attracts 50,000+ attendees and 2,000 exhibitors, showcasing pharma innovation globally.
Arvinas and Pfizer present promising Phase 1b data on vepdegestrant and abemaciclib for breast cancer at San Antonio Breast Cancer Symposium 2024.
aTyr Pharma's Phase 3 EFZO-FIT™ study on efzofitimod for pulmonary sarcoidosis progresses unchanged by DSMB.
Zealand Pharma enrolls first participant in ZUPREME-1 trial, testing petrelintide for obesity and weight-related conditions.
Ketamir-2 by MIRA achieves preclinical safety milestone, paving the way for trials targeting neuropathic pain in 2025.
Baxter's 2024 launches include injectables for infections, cancer, GERD, seizures, enhancing efficiency and safety.
Pharma Now’s Nov-Dec edition explores pharma machinery breakthroughs, leadership insights, and coverage from key industry events.
AbbVie completes the acquisition of Aliada, focusing on ALIA-1758, an Alzheimer's drug with CNS-targeting technology.
Astria’s STAR-0215 shows 90-95% attack reduction in HAE trial, entering Phase 3 in 2025 with strong safety results.
Phathom seeks FDA approval to extend VOQUEZNA tablets' market exclusivity to 2032, citing NCE provisions under GAIN.
OlympiA trial confirms Lynparza improves survival and reduces recurrence in high-risk breast cancer patients.
Acadia’s PRV sale of $150M focuses on investing in operations, primarily in R&D, commercial operations, and future growth opportunities.
Hepion Pharmaceuticals cancels merger with Pharma Two B Ltd. and withdraws December 12 stockholder meeting.
Monte Rosa teams up with Novartis to advance VAV1-targeted molecular glue degraders, including MRT-6160, for immune diseases.
Prelude's PRT2527 shows preliminary activity and acceptable safety in relapsed/refractory lymphoid malignancies.